BitFrontier Capital Holdings, Inc. (OTC: BFCH), operating as EVERMIND Holdings, Inc., has entered into a binding Letter of Intent (LOI) to acquire ERApeutics, LLC, the creator of the EVERMIND™ beverage platform. This acquisition, valued at $4,000,000 through the issuance of 400,000,000 restricted common shares at $0.01 per share, signifies BFCH's commitment to expanding its footprint in the cognitive health sector.
EVERMIND™ is a physician-formulated, plant-based protein shake designed to support brain health with both immediate and long-term benefits. The brand, which is shelf-stable and backed by scientific research, is poised for commercialization. This move not only adds a valuable asset to BFCH's portfolio but also aligns with the company's strategy to strengthen its balance sheet and meet the $0.01 equity benchmark, a critical step towards its OTCQB uplisting.
Dr. Jordan Balencic, CEO of BFCH, highlighted the potential of EVERMIND™ to revolutionize the cognitive health beverage market, drawing parallels to the success of Celsius in the metabolism sector. The EVERMIND™ platform includes six proprietary formulations, an R&D pipeline, and a fully integrated e-commerce system, positioning BFCH as a key player in the functional beverage industry.
The acquisition is expected to close within 60 to 90 days, pending due diligence. This transaction underscores the growing institutional interest in functional beverages, as evidenced by recent investments from major players like Keurig Dr Pepper and Coca-Cola. EVERMIND™ offers a unique opportunity in this space, focusing on mental clarity, mood, and cognitive performance.
For more details on the EVERMIND™ platform and its potential impact on the cognitive health market, visit https://evermindholdings.com/evermind-beverage/.
